Last reviewed · How we verify
NCT04785209
Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
trial testing Mean platelet volume, lymphocyte number, STEMI clinical risk scores in No-Reflow Phenomenon in 640 participants. Completed in 1 May 2024.
28 February 2021
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 640 |
| Start date | 1 September 2020 |
| Primary completion | 28 February 2021 |
| Estimated completion | 1 May 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Mean platelet volume, lymphocyte number, STEMI clinical risk scores
Conditions studied
- No-Reflow Phenomenon — all drugs for No-Reflow Phenomenon →
Sponsor
Assiut University
Who can join
16 and older, any sex, with No-Reflow Phenomenon. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Predicting no reflow in ppci of STEMI patients using mean platelet volume together with STEMI clinical risk scores
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04785209
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for No-Reflow Phenomenon
Currently open trials in the same condition.
- NCT07536802 — Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial · Phase 4 · recruiting
- NCT06342141 — Empagliflozin for No-reflow Phenomenon in PCI for STEMI · Phase 2 · active not recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04785209 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 31 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04785209.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing